Heidelberg Pharma AG represents core values of innovation, excellence, and integrity in the pharmaceutical industry. With a strong corporate philosophy, the company focuses on developing innovative therapies for the treatment of cancer and other diseases. Heidelberg Pharma AG is committed to advancing scientific research and utilizing cutting-edge technologies to discover and develop novel therapeutic solutions. By prioritizing collaboration and partnership, the company aims to foster sustainable growth and bring transformative therapies to patients worldwide. Heidelberg Pharma AG's corporate philosophy underscores its dedication to improving patient outcomes and driving advancements in the field of oncology.

Heidelberg Pharma AG is primarily present in Germany and Europe.

Heidelberg Pharma AG has achieved several significant milestones. The company successfully developed its proprietary technology platform, Antibody Targeted Amanitin Conjugates (ATAC), which enables the targeted delivery of potent anti-cancer drugs to tumor cells. They have also entered into important strategic partnerships, including collaborations with big pharmaceutical companies, for the development and commercialization of their drug candidates. Additionally, Heidelberg Pharma AG has successfully completed preclinical and clinical studies, demonstrating the potential effectiveness and safety of their ATAC compounds in treating various types of cancers. These milestones highlight the company's commitment to innovation and its potential to make a significant impact in the field of oncology.

Heidelberg Pharma AG is a German biopharmaceutical company specializing in the development of innovative therapeutic drugs for various cancers. Founded in 1997, the company has a rich history of research, collaborations, and breakthrough discoveries. Over the years, Heidelberg Pharma AG has become a leader in the field of antibody-drug conjugates (ADCs), a cutting-edge technology that allows targeted delivery of potent anti-cancer agents to tumor cells. By utilizing their proprietary technology platform, the company aims to develop safer and more effective treatments for patients with unmet medical needs. Heidelberg Pharma AG continues to grow and advance its pipeline, working towards revolutionizing cancer care worldwide.

The main competitors of Heidelberg Pharma AG in the market are companies such as Celgene Corporation, Gilead Sciences Inc., and Johnson & Johnson. These pharmaceutical companies operate in the same industry as Heidelberg Pharma AG and offer similar products and services. Competitor analysis plays a crucial role in the strategic planning and decision-making process for Heidelberg Pharma AG to maintain its competitive edge and market share.

Heidelberg Pharma AG is primarily active in the pharmaceutical industry.

The business model of Heidelberg Pharma AG is focused on developing innovative antibody-based therapies for oncology. The company utilizes its proprietary technology platform, called Antibody Targeted Amanitin Conjugate (ATAC), which combines the specificity of antibodies with the potency of Amanitin, a toxin found in the death cap mushroom. This approach targets cancer cells more effectively while sparing healthy tissue, leading to improved efficacy and reduced side effects. Heidelberg Pharma AG collaborates with pharmaceutical companies to develop and commercialize ATAC candidates. By leveraging its expertise in drug discovery and development, the company aims to provide novel and targeted treatments for cancer patients worldwide.

Heidelberg Pharma KGV ir -5,36.

Heidelberg Pharma KUV ir 10,74.

AlleAktien kvalitātes vērtējums Heidelberg Pharma ir 2/10.

gaidāmā Heidelberg Pharma apgrozījums ir 10,20 milj. EUR.

gaidāmā Heidelberg Pharma peļņa ir -20,44 milj. EUR.

Heidelberg Pharma AG is a company specialized in the research and development of cancer therapies in the biotechnology industry. Its business model is based on the use of its own ADC technology platform (Antibody-Drug Conjugates) for the identification and development of new cancer drugs. The company operates in two main business areas: pharmaceutical research and clinical development. In pharmaceutical research, the focus is on identifying and validating new target proteins for cancer drugs using advanced methods of genetics, proteomics, and cell biology. In clinical development, the company concentrates on developing cancer drugs using its ADC technology platform. ADCs consist of an antibody that selectively binds to the desired target protein in the tumor, and a chemical drug. Once the antibody recognizes the target protein, the drug is activated and destroys the cancer cell. This ensures that the drug is released only in the tumor and spares healthy cells. Heidelberg Pharma has an extensive portfolio of ADCs currently in various phases of clinical studies, including the drug HDP-101 for the treatment of various solid tumors. The company also addresses other types of cancer such as multiple myeloma, lung cancer, and pancreatic cancer. Its business model is based on the complete control of its ADC technology platform, as well as the extensive experience and know-how built in cancer research and drug development. Strategic licensing and cooperation partnerships are used to advance the development of its cancer drugs, aiming to achieve efficiency gains and reduce product failure risks. Overall, Heidelberg Pharma's business model is characterized by a strong and efficient ADC technology platform, extensive experience in cancer research, successful clinical developments, and strategic partnerships. All of these factors will contribute to the company's future growth and establishment as a significant player in cancer treatment.

Heidelberg Pharma izmaksā dividendes 0 EUR, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Heidelberg Pharma vai uzņēmums nedod dividendes.

Heidelberg Pharma ISIN ir DE000A11QVV0.

Heidelberg Pharma WKN ir A11QVV.

Heidelberg Pharma simbols ir HPHA.DE.

Pēdējo 12 mēnešu laikā Heidelberg Pharma maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Heidelberg Pharma plāno maksāt dividendes 0 EUR apmērā.

Heidelberg Pharma pašreizējā dividendu rentabilitāte ir .

Heidelberg Pharma maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Heidelberg Pharma pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 EUR. Tas atbilst dividendes ražībai 0 %.

Heidelberg Pharma tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Heidelberg Pharma apmērā 0 EUR, kas tika izmaksāta 3.12.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 3.12.2024..

Pēdējās dividendes izmaksa notika 3.12.2024..

Gadā 2023, Heidelberg Pharma izmaksāja 0 EUR dividendes.

Heidelberg Pharma dividendes tiek izmaksātas EUR.